-
公开(公告)号:US20240368144A1
公开(公告)日:2024-11-07
申请号:US18311266
申请日:2023-05-03
Applicant: Pfizer Inc.
Inventor: Brian Stephen Gerstenberger , Andrew Christopher Flick , Daniel Wei-Shung Kung , Vincent Michael Lombardo , James John Mousseau , Philippe Marcel Nuhant , Ralph Pelton Robinson, JR. , Daniel Copley Schmitt , Mark Edward Schnute , Atli Thorarensen , John Isidro Trujillo , Rayomand Jal Unwalla , Huixian Wu
IPC: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/6558
Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
-
公开(公告)号:US20210206757A1
公开(公告)日:2021-07-08
申请号:US17192968
申请日:2021-03-05
Applicant: Pfizer Inc.
Inventor: Brian Stephen Gerstenberger , Andrew Christopher Flick , Daniel Wei-Shung Kung , Vincent Michael Lombardo , James John Mousseau , Philippe Marcel Nuhant , Ralph Pelton Robinson, JR. , Daniel Copley Schmitt , Mark Edward Schnute , Atli Thorarensen , John Isidro Trujillo , Rayomand Jal Unwalla , Huixian Wu
IPC: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/6558
Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
-
公开(公告)号:US10426135B2
公开(公告)日:2019-10-01
申请号:US16268857
申请日:2019-02-06
Applicant: Pfizer Inc.
Inventor: Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Goran Mattias Wennerstal , Li Xing , Edouard Zamaratski , Liying Zhang , Rayomand Jal Unwalla
IPC: C07D401/02 , C07D401/10 , A61K31/437 , A61K31/4353 , A01K5/01 , B65D77/20 , B65D25/04 , B65D1/34 , A01K7/00 , A23K20/00 , A23K50/48 , B65D1/36 , B65D25/18 , B65D85/00
Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
-
公开(公告)号:US20140243312A1
公开(公告)日:2014-08-28
申请号:US14183946
申请日:2014-02-19
Applicant: Pfizer Inc.
Inventor: Matthew Frank Brown , Ashley Edward Fenwick , Mark Edward Flanagan , Andrea Gonzales , Timothy Allan Johnson , Neelu Kaila , Mark J. Mitton-Fry , Joseph Walter Strohbach , Ruth E. TenBrink , John David Trzupek , Rayomand Jal Unwalla , Michael L. Vazquez
IPC: C07D487/04
CPC classification number: A61K31/519 , A61K31/5386 , C07D207/18 , C07D487/04 , C07D519/00
Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
Abstract translation: 本文描述的是吡咯并[2,3-d]嘧啶衍生物,它们用作Janus Kinase(JAK)抑制剂,以及含有它们的药物组合物。
-
公开(公告)号:US10703756B2
公开(公告)日:2020-07-07
申请号:US15569874
申请日:2016-04-19
Applicant: Pfizer Inc.
Inventor: Atli Thorarensen , Matthew Frank Brown , Agustin Casimiro-Garcia , Ye Che , Mark Edward Flanagan , Adam Matthew Gilbert , Matthew Merrill Hayward , Jean-Baptiste Telliez , Rayomand Jal Unwalla , John I. Trujillo , Sidney Xi Liang
IPC: C07D487/04
Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides, and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
-
公开(公告)号:US09549929B2
公开(公告)日:2017-01-24
申请号:US14715046
申请日:2015-05-18
Applicant: Pfizer Inc.
Inventor: Matthew Frank Brown , Ashley Edward Fenwick , Mark Edward Flanagan , Andrea Gonzales , Timothy Allan Johnson , Neelu Kaila , Mark J. Mitton-Fry , Joseph Walter Strohbach , Ruth E. TenBrink , John David Trzupek , Rayomand Jal Unwalla , Michael L. Vazquez , Mihir D. Parikh
IPC: A61K31/519 , C07D487/04 , C07D519/00 , A61K31/5386 , C07D207/18
CPC classification number: A61K31/519 , A61K31/5386 , C07D207/18 , C07D487/04 , C07D519/00
Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
Abstract translation: 本文描述的是吡咯并[2,3-d]嘧啶衍生物,它们用作Janus Kinase(JAK)抑制剂,以及含有它们的药物组合物。
-
公开(公告)号:US09328104B2
公开(公告)日:2016-05-03
申请号:US14093812
申请日:2013-12-02
Applicant: Pfizer Inc.
Inventor: James Thomas Anderson , Eugene Lvovich Piatnitski Chekler , Edmund L. Ellsworth , Bruce Kipp Erickson , Adam Matthew Gilbert , Anthony P. Ricketts , David P. Thompson , Rayomand Jal Unwalla , Patrick Robert Verhoest
IPC: C07D207/08 , C07D211/22 , C07D217/26 , C07D285/10 , C07D401/04 , C07D417/04 , C07C255/59 , C07C255/58 , C07D205/04
CPC classification number: C07D417/04 , C07C255/58 , C07C255/59 , C07D205/04 , C07D207/08 , C07D211/22 , C07D217/26 , C07D285/10 , C07D401/04
Abstract: The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or —CR0—, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, etc., Z is —CRe—, or, —N—, where Re is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R1 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R2 are independently hydrogen or C1-C6 linear or branched chain alkyl; R3 and R4 are independently hydrogen, C1-C6 linear or branched chain alkyl, etc.; R5 and R6 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; R8 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R9 and R10 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; Q is —CO—, —(CH2)q—, —(CHRs)q—, or —(CRsRt)q—, where Rs and Rt are independently C1-C6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.
Abstract translation: 本发明涉及式1,2或3的化合物:其中A是N或-CR 0-,其中R 0是氢,C 1 -C 6直链或支链烷基等,Z是-CRe-或 - N-,其中Re为氢,C1-C6直链或支链烷基等; R1是氢,C1-C6直链或支链烷基等; R2独立地为氢或C1-C6直链或支链烷基; R3和R4独立地是氢,C1-C6直链或支链烷基等; R5和R6独立地是氢或C1-C6直链或支链烷基等; R8是氢,C1-C6直链或支链烷基等; R9和R10独立地为氢或C1-C6直链或支链烷基等; Q是-CO - , - (CH2)q-, - (CHRs)q-或 - (CRsRt)q-,其中Rs和Rt独立地是C1-C6直链或支链烷基,芳基,烷基芳基,杂芳基或烷基杂芳基 ; 其中q是0,1,2或3; 并且其中n为0,1,2,3,4或5; 或其药学上可接受的盐包含含有这些化合物的组合物; 以及这些化合物在治疗各种疾病,特别是受雄激素受体影响或介导的疾病的用途。
-
公开(公告)号:US20150225408A1
公开(公告)日:2015-08-13
申请号:US14691606
申请日:2015-04-21
Applicant: Pfizer Inc.
Inventor: Matthew Frank Brown , Ashley Edward Fenwick , Mark Edward Flanagan , Andrea Gonzales , Timothy Allan Johnson , Neelu Kaila , Mark J. Mitton-Fry , Joseph Walter Strohbach , Ruth E. TenBrink , John David Trzupek , Rayomand Jal Unwalla , Michael L. Vazquez , Mihir D. Parikh
IPC: C07D487/04 , C07D519/00
CPC classification number: A61K31/519 , A61K31/5386 , C07D207/18 , C07D487/04 , C07D519/00
Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
-
公开(公告)号:US11708360B2
公开(公告)日:2023-07-25
申请号:US17192968
申请日:2021-03-05
Applicant: Pfizer Inc.
Inventor: Brian Stephen Gerstenberger , Andrew Christopher Flick , Daniel Wei-Shung Kung , Vincent Michael Lombardo , James John Mousseau , Philippe Marcel Nuhant , Ralph Pelton Robinson, Jr. , Daniel Copley Schmitt , Mark Edward Schnute , Atli Thorarensen , John Isidro Trujillo , Rayomand Jal Unwalla , Huixian Wu
IPC: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/6558
CPC classification number: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/65583
Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B)
or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.-
10.
公开(公告)号:US20230009153A1
公开(公告)日:2023-01-12
申请号:US17393463
申请日:2021-08-04
Applicant: Pfizer Inc.
Inventor: Atli Thorarensen , Matthew Frank Brown , Agustin Casimiro-Garcia , Ye Che , Jotham Wadsworth Coe , Mark Edward Flanagan , Adam Matthew Gilbert , Matthew Merrill Hayward , Jonathan David Langille , Justin Ian Montgomery , Jean-Baptiste Telliez , Rayomand Jal Unwalla , John I. Trujillo
IPC: C07D471/04 , A61K31/4523 , C07D471/08 , C07D487/04 , C07D487/10 , C07D498/04
Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
-
-
-
-
-
-
-
-
-